Home

Biotech

Broadband

B2B Internet

Europe 2001

Internet

Internet 
Architecture

Internet 
Infrastructure

Market 2000+

Oil Services

Pharmaceutical

Regional Bank

Retail

Semiconductor

Software

Telecom

Utilities

Wireless
Johnson & Johnson (NYSE:JNJ)7/28/2010
most recent headlinesmore headlines:       
THURSDAY, JULY 29, 2010
5:34 AMDiamyd Medical receives USD45m upfront payment for diabetes vaccine - M2
MONDAY, JULY 26, 2010
6:44 PMGlaxoSmithKline, Johnson & Johnson, Pfizer, AstraZeneca and More Present at the 6th Compound Management & Integrity Conference in Philadelphia, PA - BusinessWire
TUESDAY, JULY 20, 2010
10:25 AMCorporate Counsel Reports Recession and Executive Pay Scrutiny Hit Compensation for Top General Counsel - BusinessWire
10:00 AMThe Launch and Uptake of Nine Emerging Therapies Will Drive the Prostate Cancer Drug Market to More Than Double to $8.4 Billion in 2019 - PR Newswire
7:45 AMJohnson & Johnson Reports 2010 Second-Quarter Results: - PR Newswire
MONDAY, JULY 19, 2010
5:00 PMFormer McKinsey & Company Chairman and Managing Director Ian Davis Appointed to Johnson & Johnson Board of Directors - PR Newswire
FRIDAY, JULY 16, 2010
5:01 AMUS anti-trust authorities okay Diamyd Medical diabetes vaccine deal - M2
WEDNESDAY, JULY 14, 2010
4:22 PMMicrus Endovascular Board Being Investigated by The Law Office of Joseph Klein Following Johnson & Johnson Bid - MEND - BusinessWire
1:31 PMBull & Lifshitz, LLP Announces Investigation of the Acquisition of Micrus Endovascular Corporation - BusinessWire
TUESDAY, JULY 13, 2010
3:33 PMThe Briscoe Law Firm, PLLC and Cash Powers Taylor, LLP Announce Shareholder Investigation into the Acquisition of Micrus Endovascular Corporation - BusinessWire


Quotes delayed at least 15 minutes. Market data provided by Interactive Data.
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

HOLDRS Defined |  HOLDRS Outstanding  |  FAQ  |  Proxies by email  |  Investment Strategies
Spin-Offs & Changes  |  Current Trading  |  Download a Prospectus  |  Site Map

Merrill Lynch, Pierce, Fenner & Smith Incorporated is a registered broker-dealer and a wholly-owned subsidiary of Bank of America Corporation.
Securities Products: Are Not FDIC Insured • Are Not Bank Guaranteed • May Lose Value.

The information in this Internet site is directed at, and is intended for distribution to, and for use by, persons in the U.S. only, and is not intended for distribution to or use by any person in any other jurisdiction. Merrill Lynch does not warrant the accuracy or completeness of any price, tax, cost basis, or other information on this site, or any investment, tax or other benefits associated with HOLDRS.

The information on HOLDRSSM contained in this Internet site is solely for informational purposes and does not constitute either an offer to sell or the solicitation of an offer to buy HOLDRS. This information on HOLDRS is not, and is not intended to be, a complete discussion of all material information you should know about HOLDRS. If you are considering whether to purchase a HOLDRS security, you should carefully read the relevant prospectus prior to making a purchase. You should not rely on the information contained in this Internet site. Please view Terms of Use and Legal Notices for additional important legal information and the terms and conditions governing your use of this site.

U.S. Patent Pending.
HOLDRS and HOLding Company Depositary ReceiptS are service marks of Merrill Lynch & Co., Inc.

© Copyright 2000, Merrill Lynch, Pierce, Fenner & Smith Incorporated. Member, Securities Investor Protection Corporation (SIPC). All rights reserved.